Patents Assigned to Suven Life Science Limited
-
Publication number: 20130085145Abstract: The present invention provides a pharmaceutical tablet, comprising Imatinib in an amount of 50-75% w/w of the total tablet weight and comprising at least one pharmaceutically acceptable excipient without a binding agent and the process for preparation of the same.Type: ApplicationFiled: January 10, 2011Publication date: April 4, 2013Applicant: SUVEN LIFE SCIENCES LIMITEDInventor: Ravula Sayisiva Prasad
-
Patent number: 8404720Abstract: The present invention relates to novel aryl sulfonamide amine compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them.Type: GrantFiled: March 3, 2009Date of Patent: March 26, 2013Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Rama Sastri Kambhampati, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Publication number: 20130072518Abstract: The present invention relates to novel bicyclic compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment and prevention of various disorders that are related to ?4?2 nicotinic receptors.Type: ApplicationFiled: December 31, 2009Publication date: March 21, 2013Applicant: Suven Life Science LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Srinivas Veeramalla, Srinivasa Rao Ravella, Ishtiyague Ahmad, Pradeep Jayarajan, Anil Karbhari Shinde, Rama Sastri Kambhampti, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Publication number: 20130005709Abstract: The present invention relates to novel sulfone compounds as 5-HT6 receptor ligands of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment/prevention of various disorders that are related to 5-HT6 receptor functions.Type: ApplicationFiled: March 24, 2010Publication date: January 3, 2013Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Rama Sastri Kambhampati, Rajesh Kumar Badange, Veena Reballi, Anil Kashinath Chindhe, Rambabu Namala, Mohamad Sadik Abdulhamid Mulla, Ishtiyaque Ahmad, Renny Abraham, Venkateswarlu Jasti
-
Publication number: 20120322808Abstract: The present invention relates to novel ?4?2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. The present invention relates to novel ?4?2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them.Type: ApplicationFiled: May 3, 2010Publication date: December 20, 2012Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Kana Ram Kumawat, Ishtiyaque Ahmad, Pradeep Jayarajan, Anil Karbhari Shinde, Nagaraj Vishwottam Kandikere, Koteshwara Mudigonda, Venkateswarlu Jasti
-
Publication number: 20120315657Abstract: The present invention provides novel functional assay for 5-HT2A, histamine H1 or adrenergic alpha 1b receptors, by measuring intracellular cyclic adenosine monophosphate (cAMP) levels utilizing reporter gene driven cell based assay. The novel assay provides both binding affinity as well as mode of action of compounds in a single set. The novel assay of the invention is useful in identification of compounds acting through 5-HT2A, histamine H1 or adrenergic alpha 1b receptors. Furthermore, the assay offers utility in categorizing compounds in to agonist, partial agonist, inverse agonist and antagonist classes. The novel assay can be scaled up to any high throughput format.Type: ApplicationFiled: March 31, 2010Publication date: December 13, 2012Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ishtiyaque Ahmad, Reddy Venkat Mekala, Reddy Muddukrishna Chillakur, Ramkumar Subramaniam, Jyothsna Ravula, Sriramachandra Murthy Patnala, Ramakrishna Nirogi, Venkateswarlu Jasti
-
Patent number: 8318725Abstract: The present invention relates to novel aryl indolyl sulfonamide compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them.Type: GrantFiled: March 3, 2009Date of Patent: November 27, 2012Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Rama Sastri Kambhampati, Anil Karbhari Shinde, Ishtiyaque Ahmad, Nagaraj Vishwottam Kandikere, Venkateswarlu Jasti
-
Publication number: 20120277216Abstract: The present invention relates to novel 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The compounds of the present invention are useful in the treatment/prevention of various disorders that are mediated by 5-HT4 receptor activity.Type: ApplicationFiled: December 29, 2009Publication date: November 1, 2012Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Ishtiyaque Ahmad, Pradeep Jayarajan, Nagaraj Vishwottam Kandikere, Anil Karbhari Shinde, Rama Sastri Kambhampati, Gopinadh Bhyrapuneni, Jyothsna Ravula, Sriramachandra Murthy Patnala, Venkateswarlu Jasti
-
Publication number: 20120129816Abstract: The present invention relates to novel aryl sulfonamide amine compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them.Type: ApplicationFiled: March 3, 2009Publication date: May 24, 2012Applicant: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Rama Sastri Kambhampati, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Patent number: 8143303Abstract: Carbazole derivatives of formula (I), useful in treatment of a CNS disorders related to or affected by the 5-HT6 receptor are described. The pharmacological profile of these compounds includes high affinity binding with 5-HT6 receptor along with good selectivity towards the receptor. Stereoisomers, the salts, methods of preparation and medicines containing the carbazole derivatives are also described.Type: GrantFiled: June 9, 2006Date of Patent: March 27, 2012Assignee: Suven Life Sciences LimitedInventors: Venkata Satya Nirogi Ramakrishna, Rama Sastri Kambhampati, Vikas Shreekrishna Shirsath, Jagadish Babu Konda, Santosh Vishwakarma, Venkateswarlu Jasti
-
Patent number: 8138366Abstract: The present invention relates to the improved process for the preparation of highly pure form of S-[1,2-(dicarbethoxy)-ethyl]O,O-dimethyl phosphorodithioate having formula (I). The compound of formula (I) has adopted name “Malathion”. The present invention also relates to the novel process of preparing intermediate O,O-dimethyldithiophosphoric acid of formula (II), which is useful in the preparation of Malathion.Type: GrantFiled: April 28, 2008Date of Patent: March 20, 2012Assignee: Suven Life Sciences LimitedInventors: Veera Reddy Arava, Vaishali Nadkarni, Venkateswarlu Jasti
-
Publication number: 20110281849Abstract: The present invention relates to novel aryl indolyl sulfonamide compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them.Type: ApplicationFiled: March 3, 2009Publication date: November 17, 2011Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Rama Sastri Kambhampati, Anil Karbhari Shinde, Ishtiyaque Ahmad, Nagaraj Vishwottam Kandikere, Venkateswarlu Jasti
-
Patent number: 8003670Abstract: The present invention relates to novel aminoalkoxy arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardiovascular diseases and cancer.Type: GrantFiled: April 15, 2008Date of Patent: August 23, 2011Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Rama Sastri Kambhampati, Anil Karbhari Shinde, Anand Vijaykumar Daulatabad, Adi Reddy Dwarampudi, Nagaraj Vishwottam Kandikere, Santosh Vishwakarma, Venkateswarlu Jasti
-
Patent number: 7998981Abstract: The present invention provides aminoaryl sulphonamide derivatives of formula (I), useful in the treatment of a CNS disorder related to or affected by the 5-HT6 receptor. Pharmacological profiles of these components include high affinity binding with 5-HT6 receptors along with good selectivity towards the receptor. The present invention also includes stereoisomers, the salts, methods of preparation and medicine containing the aminoaryl sulphonamide derivatives.Type: GrantFiled: October 26, 2005Date of Patent: August 16, 2011Assignee: Suven Life Sciences LimitedInventors: Venkata Satya Nirogi Ramakrishna, Vikas Shreekrishna Shirsath, Rama Sastri Kambhampati, Santosh Vishwakarma, Nagaraj Vishwottam Kandikere, Srinivasulu Kota, Venkateswarlu Jasti
-
Patent number: 7964627Abstract: The present invention relates to novel amino arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them: The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The compounds of the invention are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, obesity, anxiety, depression, diseases associated with pain, respiratory diseases, gastrointestinal, cardiovascular diseases and cancer.Type: GrantFiled: May 2, 2008Date of Patent: June 21, 2011Assignee: Suven Life Sciences LimitedInventors: Nirogi Venkata Satya Ramakrishna, Rama Sastri Kambhampati, Anil Karbhari Shinde, Nagaraj Vishwottam Kandikere, Venkateswarlu Jasti
-
Patent number: 7923566Abstract: The invention relates to an improved process for the preparation of Losartan. The process comprising reacting 2-n-butyl-4-chloro-5-formyl imidazole with 2-(4-bromomethyl) benzonitrile in the presence of a phase transfer catalyst and an alkali, and reducing the resulting cyano aldehyde to produce a cyano alcohol which is further reacted with sodium azide in N-methyl pyrrolidinone and a salt to produce Losartan.Type: GrantFiled: December 21, 2005Date of Patent: April 12, 2011Assignee: Suven Life Sciences LimitedInventors: Arava Veera Reddy, Siripalli Udaya Bhaskara Rao, Chinnapillai Rajendiran, Venkateswarlu Jasti
-
Patent number: 7915425Abstract: The invention relates to a improved process for the preparation of Losartan and its potassium salt, which comprises: (i) reacting bromo OTBN with BCFI in the presence of a base and a phase transfer catalyst to produce a cyano aldehyde; reacting the formed cyano aldehyde with sodium azide in the presence of tributyl tin chloride to produce aldehyde tetrazole; reducing the formed aldehyde tetrazole with sodium borohydride to produce Losartan; and, if desired, converting the formed Losartan to its potassium salt by known method.Type: GrantFiled: December 21, 2005Date of Patent: March 29, 2011Assignee: Suven Life Sciences LimitedInventors: Arava Veera Reddy, Siripalli Udaya Bhaskara Rao, Chinnapillai Rajendiran, Venkateswarlu Jasti
-
Patent number: 7875605Abstract: N-arylsulfonyl-3-substituted indole compounds, derivatives, analogs, tautomeric forms, stereoisomers, geometric forms, N-oxides, polymorphs and pharmaceutically acceptable salts.Type: GrantFiled: June 5, 2003Date of Patent: January 25, 2011Assignee: Suven Life Sciences LimitedInventors: Venkata Satya Nirogi Ramakrishna, Vikas Shreekrishna Shirsath, Rama Sastri Kambhampati, Venkata Satya Veerabhadra Vadlamudi Rao, Venkateswarlu Jasti
-
Patent number: 7872132Abstract: An improved process for the preparation of aripiprazole (1) which comprises (i) reacting 6-hydroxy-l-indanone (11) with 1,4-dihalobutane (12) in the presence of a base and a solvent at a temperature in the range of 90 to 110 deg C to form the novel intermediate 6-(4-halo butoxy)-indan-1-one (3), (ii) reacting the novel intermediate with 1-(2,3-clichlorophenyl)-piperazine (9) to get another novel intermediate 6-[4-[4-(2,3-dichlorophenyl)-l-piperazinyl]butoxy]-indan-l-one (2) and (iii) reacting the resulting novel compound with sodium azide. The invention also relates to the novel intermediates of the formulae (2) & (3) and processes for their preparation. The invention also includes intermediate compounds useful for the preparation of aripiprazole.Type: GrantFiled: October 8, 2004Date of Patent: January 18, 2011Assignee: Suven Life Sciences LimitedInventors: Rajendiran Chinnapillai, Veera Reddy Arava, Venkata Subba Rao Athukuru, Venkateswarlu Jasti
-
Publication number: 20100222597Abstract: The invention relates to a improved process for the preparation of Losartan and its potassium salt, which comprises: (i) reacting bromo OTBN with BCFI in the presence of a base and a phase transfer catalyst to produce a cyano aldehyde; reacting the formed cyano aldehyde with sodium azide in the presence of tributyl tin chloride to produce aldehyde tetrazole; reducing the formed aldehyde tetrazole with sodium borohydride to produce Losartan; and, if desired, converting the formed Losartan to its potassium salt by known method.Type: ApplicationFiled: December 21, 2005Publication date: September 2, 2010Applicant: Suven Life Sciences LimitedInventor: Arava Veera Reddy